ImPact Biotech Announces New Data Presentations at AUA 2025 Highlighting Safety and Efficacy of Padeliporfin VTP
- Company to present updated preliminary results from ENLIGHTED Phase 3 Study in LG UTUC -
- Additional podium presentation to provide updates from long-term evaluation of Padeliporfin VTP in intermediate-risk prostate cancer -
TEL AVIV, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that the company will present updated preliminary results from ENLIGHTED, the Company's ongoing Phase 3 study of Padeliporfin VTP treatment in patients with low-grade upper tract urothelial cancer (UTUC), as well as long-term follow up from the PCM-204 Phase 2b trial evaluating Padeliporfin VTP in men with intermediate risk of prostate cancer, at the American Urological Association's 2025 Annual Meeting taking place April 26-29, 2025 in Las Vegas, Nevada.
'We are excited for the opportunity to share positive updates from the ENLIGHTED trial, which we believe will continue to reinforce Padeliporfin VTP's potential to shift the treatment paradigm as a promising non-invasive option for patients with low-grade UTUC,' said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. 'We also look forward to presenting results from longer-term evaluation of Padeliporfin VTP in intermediate-risk prostate cancer, where our mechanism of action is already well-understood in low-risk disease. ImPact continues to progress evaluation of Padeliporfin VTP in LG UTUC and other solid tumor indications, and we anticipate completing enrollment of the ENLIGHTED trial in 2nd half of 2025.'
Podium and Poster Session Details:
Poster Title: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC): ENLIGHTED Phase 3 Study
Presenter: Vitaly Margulis, Professor of Urologic Oncology, University of Texas Southwestern Medical CenterPoster Number: IP-12-14Session Title: Bladder Cancer: Upper Tract Transitional Cell CarcinomaSession Date & Time: April 27, 2025, 1:00 PM
Podium Session Title: 48-Month Follow up of Results of the PCM-204 Phase 2b Trial of Partial-Gland Ablation for Men with Intermediate-Risk Prostate Cancer with Padeliporfin (WST11 or Tookad) Vascular-Targeted Photodynamic TherapyPresenter: Jonathan Fainberg, Urologic Surgeon, Memorial Sloan Kettering Cancer CenterPodium Session Number: PD19-06Session Date and Time: April 27, 2025, 4:10 PM
About ENLIGHTEDThe Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across over 20 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed via a ureteroscope, applying laser fiber illumination for 10 minutes in the close vicinity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care 3 month follow ups, alongside potential single VTP treatment, for up to 12 months. The study's primary objective is to assess the efficacy and response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response.
About ImPact Biotech
ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com.
Contacts
Global Head of Business DevelopmentGuy Schmidtguy.schmidt@impactbiotech.com
Precision AQJosh Rappaportjosh.rappaport@precisionaq.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
16 hours ago
- Fast Company
Setting the standard: Understanding what it means to be a leader in your industry
What makes a company an industry leader? The simple response is the company that sells the most. Yet while sales certainly contribute to defining industry leaders, I believe leadership is more complex than this. Let's take the chemical industry as an example. It's fair to say the industry is often perceived negatively, despite the vital role chemical products play in our daily lives and the potential chemistry has to provide solutions to some of the world's biggest problems. There are many reasons for this, including its historical environmental impacts, safety concerns related to chemicals used in certain products, or even safety incidents, which still occur more often than they should. With this in mind, I want to explore what defines an industry leader in this space and how companies can stand out in an industry marked by negative perceptions. By examining leadership within the chemical industry, we can uncover universal insights into how a company's influence extends well beyond its own business environment. LEADING BY ASSOCIATION The impact a company has on the world around it goes a long way toward defining its leadership potential. From employees to customers, and local communities to the planet itself, the way a company acts will define how it's perceived and how well it operates. Impact, for me, is a company's ability to positively influence society, minimize its environmental footprint, and demonstrate care for employee well-being, while delivering impactful results for customers and shareholders. We need to do both, and we can do both. As I have already mentioned, the chemical industry has some historical perceptions to deal with, but industry-led initiatives such as the Responsible Care program, of which Syensqo is a signatory, are helping to change this. Responsible Care is designed to help chemical companies enhance their environmental, health, safety, and security (EHS&S) performance through CEO-level commitments to safety and sustainability in the communities where they operate, the products they manufacture, and the people that work for them. Membership in the right associations and programs for your company can play a significant role in defining industry leadership. Programs like Responsible Care not only hold your company to certain standards of ethics, quality, and safety, and demonstrate your company's commitment to these values, but they also keep you involved in broader industry discussions. This participation makes it easier to stay informed about industry developments, identify collaboration opportunities with peers, and advocate for both your company's and the industry's interests. It's important to note that we are not just talking about external impact or perceptions. Positive impact and leadership are driven by internal impact. If you don't have the trust, support, and confidence of your employees, you can't expect to have it from others either. For chemical companies and others, prioritizing clear and effective safety practices benefits both operations and people. It helps minimize disruptions and ensures that everyone returns home safely at the end of the day. ENSURING A POSITIVE IMPACT Committing to industry-wide initiatives puts your business on par with industry peers. It provides the foundations for leadership, but it doesn't establish leaders. To become an industry leader, you need to turn the principles promoted in such initiatives into strategic priorities that work for your business and build them into your company culture. For example, instead of viewing sustainability as something you have to do to meet regulatory requirements or other commitments, consider how it can be integrated into your business model and become an integral part of your company's identity. The Sustainable Guar Initiative (SGI) in Rajasthan, India, which was established by Syensqo (previously Solvay), in collaboration with brands such as Henkel and Procter & Gamble, and NGO TechnoServe, demonstrates how sustainability can be embedded into a company's core values. Launched in 2015, the program is celebrating its 10th anniversary this year, marking a decade of progress in building a more sustainable guar value chain. Guar derivatives, made from the guar bean, are used as a thickening agent, stabilizer, and conditioner in various industries. However, climate change has made farming more challenging, making crops such as guar more difficult for farmers to cultivate. The SGI aims to enhance the livelihoods of local farmers through training and education programs, introducing more sustainable and resilient agricultural practices. It also ensures that the businesses involved have a consistent and reliable supply of guar. SUSTAINABLE PRODUCT INNOVATION Product innovation is another good example of how sustainability and profitability can coexist. Decarbonization doesn't have to mean deindustrialization. Companies can be both sustainable and profitable—and those that manage to achieve this will have an advantage over the rest. Having the right tools, which promote transparency and validate the authenticity of your company's sustainability claims while aligning with your strategic priorities, can help with this. Evidence-based strategies, programs, or frameworks that you can adopt and adapt to your own business needs allow you to integrate this approach into the way you work and will give you credibility as a leader. In the chemical industry, the World Business Council for Sustainable Development's (WBCSD) Portfolio Sustainability Assessment (PSA) provides a framework that chemical companies can use as a starting point to develop their own portfolio sustainability management methodologies and processes. At the company I work for, our Sustainable Portfolio Management (SPM) tool, which is aligned with the PSA, provides scientific evidence of the sustainability impact of our products. At the same time, it helps guide company decisions across the board, shaping future innovation projects and strategic priorities, while ensuring we can meet more immediate objectives. Like the SGI, Portfolio Sustainability Assessment is about going beyond basic industry standards, this time by ensuring that the products that leave our factories make a positive impact on the world. There is a big difference—for your customers and the credibility of your business, as well as for the planet—between saying your products are sustainable and being able to prove exactly how they are sustainable. Leaders not only develop the evidence-based tools to do this; they integrate them into the way they work, setting their businesses up to do good, while also making a profit. A lot goes into defining industry leadership. However, for me, it's all about how we can achieve a lasting positive impact—because at the end of the day, if we don't have the support, trust, and loyalty of our employees, local communities, and customers, it's going to be a lot harder to make those sales!
Yahoo
a day ago
- Yahoo
From the Farm: IL Corn Growers program marks 10 years
CENTRAL ILLINOIS (WCIA) — 2025 is the 10th anniversary year for Precision Conservation Management, or PCM. It's a novel program designed to show farmers how conservation practices can be justified with a positive financial result. When PCM was announced in February of 2016, Dr. Laura Gentry of the Illinois Corn Growers' Association said it began with the challenge of getting farmers to implement conservation practices they are not currently doing. 10 years later, she and others reflect on the program's success. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- Yahoo
ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
– Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy, following single course of treatment with Padeliporfin VTP – TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that the first patient has been treated in its Phase 1 trial evaluating Padeliporfin VTP in individuals with locally advanced, unresectable pancreatic ductal adenocarcinoma (PDAC) at the UCI Irvine Medical Center. The patient, who was initially assessed as ineligible for surgical resection, received a single administration of Padeliporfin VTP. Following treatment, the tumor demonstrated changes that enabled the patient to undergo a successful pancreaticoduodenectomy (Whipple procedure) which was not previously considered feasible in this case. 'Dosing the first patient in this trial is an important milestone for ImPact and the clinical advancement of Padeliporfin VTP as we seek to extend promising observations from ENLIGHTED, our ongoing pivotal study in low-grade upper tract urothelial carcinoma, into patients with locally advanced PDAC,' said Dr. Eyal Morag, Chief Medical Officer of ImPact Biotech. 'PDAC is among the most challenging malignancies to treat, particularly where surgical intervention is not a viable option. The ability to undergo a Whipple procedure following treatment with Padeliporfin VTP, as has occurred with this first patient, underscores the potential of our platform to not only induce meaningful tumor regression but also open the door for curative surgical interventions for previously inoperable disease.' The ongoing Phase 1 trial is a two-part, multicenter, nonrandomized, open-label clinical study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Padeliporfin VTP therapy, as defined by the ability to convert inoperable patients to eligible for resection, in patients with Stage III, locally advanced, unresectable PDAC. The trial is actively enrolling in UCI Irvine Medical Center and City of Hope Medical Center. Dr. Nadine Abi-Jaoudeh, Principal Investigator at UCI Irvine Medical Center, added: 'We are absolutely thrilled by this outcome. To see an inoperable patient undergo a successful pancreaticoduodenectomy after a single treatment is truly extraordinary. This result gives us renewed hope that Padeliporfin VTP may fundamentally change the treatment landscape for pancreatic cancer patients.' As in UTUC, Padeliporfin VTP treatment in PDAC involves the intravenous administration of a photosensitizing agent, Padeliporfin, followed by targeted activation using non-thermal laser light delivered via optical fibers directly to the tumor site. This approach aims to selectively ablate tumor tissue while preserving surrounding healthy structures. Enrollment in the study is ongoing, and the Company expects preliminary data from the study in the second half of 2025. About PDACPancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer deaths, with a five-year survival rate of approximately 10% - the lowest among all solid tumors. At diagnosis, only about 20% of patients have resectable or borderline resectable disease, while the remaining 80% present with unresectable tumors that are either locally advanced or have distant metastases. Patients with unresectable tumors have limited therapeutic options and while prognoses have improved significantly in the last decade, only about 5% of patients will survive for 10 years or more following diagnosis. Therapeutic options for treatable patients remain limited and underscore significant unmet need for innovative treatments that can improve survival and quality of life. About ImPact BiotechImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) and Phase 1 study in pancreatic ductal adenocarcinoma (PDAC), with earlier stage studies ongoing or planned in high-grade UTUC and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: and the ENLIGHTED clinical trial website (for the US): Contacts Guy SchmidtGlobal Head of Business Precision AQJohn in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
